H. Lundbeck (OTC:HLBBF) Stock, Quote.Headers.trade-ideas

Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system drugs including antidepressants, antipsychotics, and antiepileptic products. The company's portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson's disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.

H. Lundbeck AS

Advanced Micro Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) is shifting its focus to the gaming GPU market, prioritizing a strategy to gain a larger market share. 
This approach marks a significant shift away from competing directly with Nvidia Corp&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) highest-end gaming GPUs, at least for now, Tom&#8217;s Hardware <a href="https://www.tomshardware.com/pc-components/gpus/amd-deprioritizing-flagship-gaming-gpus-jack-hyunh-talks-new-strategy-for-gaming-market" target="_blank" rel="noreferrer noopener">cites</a> Jack Huynh, AMD&#8217;s Senior Vice President and General Manager.
In an interview during IFA 2024, Huynh emphasized that AMD aims to capture 40%-50% of the total addressable market by focusing on mainstream and mid-range GPUs.
Nvidia currently holds 88% of the discrete GPU market, leaving AMD with just 12%, compelling the latter to focus on building scale.
AMD remains engaged in many activities to boost shareholder value as analysts continue to claim Nvidia as the key AI beneficiary.
Recently, AMD tapped Nvidia&#8217;s Keith Strier, <a target="_blank" href="https://www.benzinga.com/news/24/09/40707618/whats-going-on-with-amd-stock-on-wednesday" rel="noreferrer noopener">who was responsible</a> for boosting Nvidia&#8217;s commercial engagements with foreign governments. AMD also shared <a target="_blank" href="https://www.benzinga.com/news/24/09/40707618/whats-going-on-with-amd-stock-on-wednesday" rel="noreferrer noopener">plans to snap</a> AI server company&nbsp;ZT Systems&nbsp;for $4.9 billion as its Ryzen 9000 series failed to gain traction.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="750" height="650" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/09090425/newplot-5.png" alt="" class="wp-image-537426" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/09090425/newplot-5.png 750w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/09090425/newplot-5-300x260.png 300w" sizes="(max-width: 750px) 100vw, 750px" /></figure>
AMD has been up 28% in the last 12 months versus Nvidia, which has gained 128%.
Semiconductor and AI-linked stocks, including Nvidia and AMD, faced a continued selloff despite strong quarterly results from Nvidia and Broadcom Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>). VanEck Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMH#NASDAQ">SMH</a>) and iShares Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>) dropped over 12% in the past five days.
Price Actions: AMD stock is up 1.37% at $136.20 at the last check on Monday. NVDA is up 1.22% at $104.05.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo via Shutterstock

News

Tech

Media

AVGO

NVDA

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

AMD vs. Nvidia: AMD's Surprising Strategy Shift in Gaming GPU Battle

This article is part of Benzinga Cannabis&#8217; series ‘<a href="https://www.benzinga.com/topic/cannabis-cultivation">Cultivator Chronicles</a>,&#8217; which focuses on the latest trends, developments, and major players in the cannabis cultivation industry. Stay tuned as we dig into the world of cannabis growers and their contributions to this rapidly expanding market.
Tucked away in Snowflake, Arizona, Copperstate Farms stands as one of the largest cannabis greenhouses in North America, covering an astounding 1.7 million square feet. It's not just the size that sets this operation apart—it's the seamless blend of efficiency and environmental consciousness that powers it.
Tim Nolan, chief operating officer, brings years of experience from cannabis ventures in both Canada and Colorado and heads the operation with a focus on sustainability. "We're running a massive facility, but the way we've structured things makes it incredibly energy-efficient," Nolan explained. His goal: meet growing demand without compromising the environment.
<h3 class="wp-block-heading">Harnessing Arizona's Climate for Energy Savings</h3>
Operating at such a large scale often brings concerns about energy use, but Copperstate's location offers a distinct advantage. Nestled at 5,600 feet, Snowflake's high elevation and dry climate reduce the need for mechanical cooling and dehumidification.
"Our power usage per square foot is a fraction of what it would be in an indoor grow," Nolan pointed out, crediting the natural climate. He added, "If we were at a lower elevation, 35 feet instead of 5,500 feet, we wouldn't be able to grow there in the summer because it would be too hot." The dry air and cooler nights of Arizona's high desert help Copperstate cut down on energy consumption, allowing them to focus resources on other key production areas. "We save money on the front end and reinvest it on the back end," Nolan explained, referring to Copperstate's labor-intensive post-harvest processes.
<h3 class="wp-block-heading">Strain Development with Purpose</h3>
At Copperstate Farms, cultivating cannabis is about more than just efficiency—it's about delivering a diverse selection of high-quality strains. The company currently produces 50 strains with another 50 in development, but it's not simply about churning out new products.
"We're always evaluating the strains we bring in, seeing how they perform in this setting," Nolan said. "We don't want five strains with the same profile but different names." The focus is on offering consumers a well-rounded selection tailored to market demand and Snowflake's ideal growing conditions.
<h3 class="wp-block-heading">Sustainability and Quality, Hand in Hand</h3>
Nolan stressed that Copperstate's commitment to sustainability doesn't stop at cultivation. The savings from energy efficiency are redirected into post-harvest techniques that prioritize quality. &#8220;People are sometimes surprised at how hands-on our post-harvest process is,&#8221; Nolan admitted. "But we can operate efficiently because we aren't spending so much money on air conditioning or mechanical equipment."
By focusing on details like hand-trimming and whole-plant hanging, Copperstate can maintain a high standard in its product, even at such a large scale.
<h3 class="wp-block-heading">Positioned for the Future</h3>
With Arizona's cannabis market continuing to grow, Copperstate Farms is positioning itself to remain a leader by staying true to its environmentally responsible approach while keeping pace with evolving consumer preferences. "We're always looking ahead, making sure we're prepared for what's next," Nolan said.
By leveraging natural climate advantages and investing in sustainable practices, Copperstate Farms is setting the tone for the future of cannabis cultivation—not just growing at scale but growing responsibly.
<hr class="wp-block-separator has-alpha-channel-opacity" />
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.
Image: Shutterstock

Cannabis

Exclusives

Interview

Growing Cannabis Sustainably: Inside An Arizona 1.7 Million Square Foot Greenhouse

Management

American Airlines Is Creating Nearly 500 New Aviation Maintenance Jobs, Including More Than 385 Licensed Aviation Maintenance Technician Positions; Additional Lines Of Heavy Check Maintenance Work Being Added To Charlotte, Pittsburgh & Tulsa Maintenance Bases

Macro Economic Events

Econ #s

Economics

U.S. Energy Dept Announces Contracts Awarded For Acquisition Of 3.4M Barrels For Strategic Petroleum Reserve

Rapper Kendrick Lamar is back as a Super Bowl halftime performer, following last year's performance from Usher that was part of a<a href="https://www.benzinga.com/general/space/24/02/37109382/super-bowl-lviii-sets-modern-day-viewership-record-how-did-nfl-championship-compare-to-apollo-11-mo"> record-breaking NFL championship game.</a>
Super Bowl LIX occurs in New Orleans, Louisiana at the Caesars Superdome on Feb. 9, 2025. The game will be broadcast on Fox Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOX#NASDAQ">FOX</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOXA#NASDAQ">FOXA</a>) and feature the top two NFL teams who win the AFC and NFC Championship games.
Lamar was part of a group of rap artists who performed at Super Bowl LVI in 2022, which included Dr. Dre, Snoop Dogg, Eminem and Mary J. Blige as well.
"Rap music is still the most impactful genre to date. And I'll be there to remind the world why. They got the right one," Lamar <a href="https://www.nfl.com/news/kendrick-lamar-to-perform-at-apple-music-super-bowl-lix-halftime-show-in-new-orleans">said</a>.
NFL head of music Seth Dudowsky said the league is excited to collaborate with Kendrick and Super Bowl halftime sponsor Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) on "another unforgettable Halftime Show."
"Few artists have impacted music and culture as profoundly as Kendrick Lamar. Time and time again, Kendrick has proven his unique ability to craft moments that resonate, redefine, and ultimately shake the very foundation of hip-hop," Dudowsky said.
Lamar is a 17-time Grammy Award winner and became the first non-classical, non-jazz musician to win a Pulitzer Prize.
The rapper has often dominated the charts with "Like That" spending three weeks at number one on the Billboard Hot 100 chart earlier this year, followed by "Not Like Us" also topping the charts this summer.
Read Also: <a href="https://www.benzinga.com/general/sports/24/02/37076429/super-bowl-commercials-2024-complete-list-of-super-bowl-lviii-ads-and-companies-behind-them">Super Bowl Commercials 2024: Complete List Of Super Bowl LVIII Ads And Companies Behind Them</a>
The Winners: Apple <a href="https://www.benzinga.com/news/22/09/28980683/nfl-wins-multiyear-deal-with-apple-music-apple-music-to-sponsor-super-bowl-halftime-show">signed a deal</a> with the NFL in 2022, which kicked off with the Super Bowl Halftime Show in 2023 featuring Rihanna.
"Apple is thrilled to bring the show, starring the absolutely incomparable Kendrick Lamar, to fans worldwide with Apple Music's industry leading Spatial Audio quality along with tons of exclusive videos, interviews, playlists and so much more across Apple Music," Apple's Vice President of Apple Music Oliver Schusser said, as <a href="https://variety.com/2024/music/news/super-bowl-2025-halftime-performer-1236136777/">reported </a>by Variety.
The Apple Music Super Bowl Halftime Show featuring Usher earlier this year was the-most watched halftime show ever and earned three Emmy nominations. The Super Bowl LVII Halftime Show with Rihanna earned five Emmy nominations, becoming the first Super Bowl Halftime Show to win the Outstanding Directing for a Variety Special Emmy.
With another globally recognized artist, Apple could score big with cross-promotions of its music features and the ability to launch exclusive content for Apple subscribers.
Fox will broadcast Super Bowl LIX in 2025 and could get a boost from the halftime show. While many viewers tune in for the big game, the amount of fans tuning in for Super Bowl halftime performances is often a big factor in viewership and advertisement rates.
Super Bowl LVIII was watched by 123.4 million viewers, a Super Bowl record and figure that was up 7% year-over-year. A total of 202.4 million viewers watched a portion of the game with the halftime show seeing record viewership for any Super Bowl.
Another potential winner is Universal Music (OTC:<a class="ticker" href="https://www.benzinga.com/stock/UNVGY#OTC">UNVGY</a>)(UMGNF), which has had a hand in four of Lamar's five studio albums. 
Lamar's last album was released in 2022 and many are eagerly awaiting a new studio album. The timing of a release or announcement around the Super Bowl Halftime Show could come with potential peak interest in Lamar.
Super Bowl Halftime performers often see a substantial spike in songs and albums around the big game.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/real-estate/24/06/39507536/kendrick-lamar-cements-west-coast-victory-with-40-million-los-angeles-estate">Kendrick Lamar Cements West Coast Victory With $40 Million Los Angeles Estate</a></li>
</ul>
Image via Wikimedia Commons

Entertainment

Sports

Trading Ideas

AAPL

FOXA

UMGNF

UNVGY

Kendrick Lamar To Perform Super Bowl LIX Halftime: Could Apple, Fox And Universal Music Get A Boost?

JP Morgan analyst Anthony Paolone maintains Douglas Emmett (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DEI#NYSE">DEI</a>) with a Neutral and raises the price target from $15 to $18.

Price Target

Analyst Ratings

JP Morgan Maintains Neutral on Douglas Emmett, Raises Price Target to $18

Zealand Pharma announces positive topline results from 13-week Phase 1b multiple ascending dose clinical trial with GLP-1/GLP-2 receptor dual agonist dapiglutide
<ul>
<li>Placebo-adjusted reductions in body weight of up to a mean of 8.3% with dapiglutide after 13 weekly doses</li>
<li>Dapiglutide treatment with doses up to 13 mg was assessed to be safe and well-tolerated with gastrointestinal adverse events consistent with the profile reported with other incretin-based therapies</li>
<li>Higher doses up to 26 mg over a 28-week treatment period are being evaluated in the ongoing Part 2 of the trial with topline results expected in the first half of 2025</li>
</ul>
Copenhagen, Denmark, 9 September 2024&nbsp;– Zealand Pharma A/S ("Zealand") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZEAL#NASDAQ">ZEAL</a>), (CVR-no. 20 04 50 78), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces positive topline clinical results from a Phase 1b multiple ascending dose (MAD) trial, investigating safety, tolerability, and clinical effects of 13 weeks of dosing with dapiglutide, a long-acting GLP-1/GLP-2 receptor dual agonist in development for weight management1.

Biotech

General

ZEAL

Zealand Pharma Announces  Topline Results From 13-Week Phase 1b Multiple Ascending Dose Clinical Trial With GLP-1/GLP-2 Receptor Dual Agonist Dapiglutide; Placebo-Adjusted Reductions In Body Weight Of Up To A Mean Of 8.3% With Dapiglutide After 13 Weekly Doses

JP Morgan analyst Christopher Horvers maintains Dick's Sporting Goods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>) with a Neutral and raises the price target from $211 to $215.

JP Morgan Maintains Neutral on Dick's Sporting Goods, Raises Price Target to $215

Cantor Fitzgerald analyst Andres Sheppard reiterates Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) with a Neutral and maintains $245 price target.

Reiteration

TSLA

Cantor Fitzgerald Reiterates Neutral on Tesla, Maintains $245 Price Target

Artificial Superintelligence Alliance's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/fet/usd">FET</a>) price has increased 5.79% over the past 24 hours to $1.14, which is in the opposite direction of its trend over the past week, where it has experienced a 4.0% loss, moving from $1.2 to its current price. As it stands right now, the coin's all-time high is $3.45. 
The chart below compares the price movement and volatility for Artificial Superintelligence Alliance over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1725894223_0.png" alt="price_chart" />
The trading volume for the coin has fallen 39.0% over the past week which is opposite, directionally, with the overall circulating supply of the coin, which has increased 0.11%. This brings the circulating supply to 2.52 billion, which makes up an estimated 95.84% of its max supply of 2.63 billion. According to our data, the current market cap ranking for FET is #32 at $2.87 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1725894223_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

Movers

$FET

Cryptocurrency Artificial Superintelligence Alliance's Price Increased More Than 5% Within 24 hours

Axtra3D printing capabilities complement digital manufacturer's advanced photopolymer offering with highly precise and repeatable printed parts in days.
Digital manufacturing leader Protolabs expanded its 3D printing capabilities today with the launch of an <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.protolabs.com%2Fservices%2F3d-printing%2Fadvanced-photopolymers%2F&amp;esheet=54118617&amp;newsitemid=20240909892648&amp;lan=en-US&amp;anchor=advanced+photopolymers+technology&amp;index=1&amp;md5=6d53469f2c8adbd656e5c371c04611e0">advanced photopolymers technology</a>. Axtra3D Hybrid PhotoSynthesis (HPS) offers highly repeatable and finely detailed 3D printed parts at accelerated speeds. HPS uses both a precision laser and digital light processing (DLP) system to simultaneously image internal and external part structures—a dual 3D printing approach that overcomes traditional limitations.
HPS complements Protolabs' current Carbon digital light synthesis (DLS) printers for 3D printing projects that require stronger mechanical properties. Both Carbon DLS and HPS feature near-isotropic parts and smooth surface finishes, but HPS technology also offers exceptionally high resolution when compared to other 3D printing processes.

PRLB

Protolabs Expands 3D Printing Options with Hybrid PhotoSynthesis Technology; Axtra3D Hybrid Photosynthesis Offers Highly Repeatable And Finely Detailed 3D Printed Parts At Accelerated Speeds

While many are excited about the potential of AI, it does come with a large environmental impact, data hygiene issues, and other concerns. AI is powered by resource-intensive servers which consume huge amounts of energy. Data storage centers (server farms) account for more than 1% of global energy.&nbsp;
These giant server farms back up everything from government records to social media profiles to corporate data, and AI greatly exacerbates this rise. A single query from OpenAI's ChatGPT uses ten times more electricity than a Google query.&nbsp;
Researchers estimate that the computational power cost required to train AI models <a href="https://www.discovermagazine.com/technology/ai-machines-have-beaten-moores-law-over-the-last-decade-say-computer" rel="nofollow">doubles every six months</a>. Data centers further require a huge amount of water for cooling, burning another precious resource. 
In the near future, online content could be more than 99% AI-generated, rendering the internet unrecognizable. Plus, AI agents will also be playing an increasing role in human activities to execute tasks.&nbsp;
<h2 class="wp-block-heading">Introducing AI Agents</h2>
An AI agent independently fulfills duties on behalf of users. This can include booking flight tickets or hiring an employee. The human sets the goals, while the AI agent acts autonomously to execute the task in the most efficient manner.&nbsp;
To do this, they could access your email, calendar, contacts, messages, etc, as well as accessing a multitude of third-party apps to execute transactions. This will involve many RPC and API calls, requiring significant resources and testing. However, it could vastly improve the human experience having benefits in terms of customer service, cost reduction, and improved efficiency.&nbsp;
These AI agents will work from foundational LLMs, such as ChatGPT. At present, AI agents are still very much developmental and there are ethical considerations to account for, such as data privacy and resource usage. There are a multitude of AI agent types to be developed including simple reflex, model-based reflex, goal-based agents, utility-based agents, learning agents, hierarchical agents, etc.&nbsp;
Such AI agents could drastically reduce the time spent on prompt engineering; a once-exciting field could be rendered redundant in a surprisingly short space of time, depending on other related innovations. They will have applications in multiple industries, including healthcare, insurance, gaming, education, etc.&nbsp;
<h2 class="wp-block-heading">Data Suggests That Agents Are The Future of AI&nbsp;</h2>
According to Gartner, 33% of AI interaction could be <a href="https://www.gartner.com/en/newsroom/press-releases/2024-03-11-gartner-predicts-one-third-of-interactions-with-genai-services-will-use-action-models-and-autonomous-agents-for-task-completion-by-2028">done through agents</a> as soon as 2028, less than four years time. The first wave of such agents will likely be focused on chat agents instead of more sophisticated, multidimensional models. AI agents can act as specialized self-learning employees dedicated to a distinct function.&nbsp;
AI chat agents turn out higher-quality content and reduce review times in comparison to typical AI-powered chatbots. Google, Microsoft, and Amazon have all admitted to building AI agents and even dedicated power stations to support them.&nbsp;
In the realm of financial services, an AI agent could detect financial fraud as it is happening, alerting the appropriate authorities and instigating security procedures. Within marketing, they could monitor budgets and proactively identify opportunities for expansion. In HR, candidates could be interviewed and hired/rejected based on performance, with little overhead.&nbsp;
Currently, most organizations are not prepared to leverage AI agents. But this is largely because the infrastructure is not there yet. Startups could be very active in the next few years pushing forward AI agent technology; it could prove to be a lucrative field as the next major technological development on the planet.
<h2 class="wp-block-heading">Supporting AI Agent Development</h2>
The sheer volume of data is growing relentlessly, and non-AI systems can&#8217;t keep up. It's only natural to assume that AI will be responsible for the majority of data processing. Yet in order for AI agents to make purchasing decisions on behalf of users, an essential function, the data needs to be transactional and trusted. These are words long associated with blockchain, a far more efficient architecture than the traditional server model.&nbsp;
This is especially true when the disparate networks begin to work synergistically, with full cross-chain interoperability. It's a known fact that the combined output of individual components working together generates an output far greater than each working in isolation. It could also help reduce the growing environmental burden associated with continual AI development.&nbsp;
Blockchain is the perfect infrastructure to assist AI agents in executing economic transactions for users, instead of simply interpreting data. However, the blockchain architecture itself needs to be re-engineered until it can accurately parse data and feed it to these economic AI agents. Until then, we are unlikely to see AI agents really take off, as they have no working architecture.&nbsp;
In sum, AI agents are perfectly suited to blockchain, but only when on-chain data is made more readily available for consumption.&nbsp;

99% Of Data Will Be Consumed By AI Agents, Supported With Blockchain

Uniswap's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/uni/usd">UNI</a>) price has increased 3.84% over the past 24 hours to $6.55. Over the past week, UNI has experienced an uptick of over 9.0%, moving from $6.04 to its current price. As it stands right now, the coin's all-time high is $44.92. 
The chart below compares the price movement and volatility for Uniswap over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1725894154_0.png" alt="price_chart" />
The trading volume for the coin has tumbled 30.0% over the past week while the circulating supply of the coin has risen 0.47%. This brings the circulating supply to 753.77 million, which makes up an estimated 75.38% of its max supply of 1.00 billion. According to our data, the current market cap ranking for UNI is #23 at $4.94 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1725894154_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$UNI

Cryptocurrency Uniswap Rises More Than 3% In 24 hours

Over the past 24 hours, NEAR Protocol's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/near/usd">NEAR</a>) price has risen 4.14% to $3.84. This is contrary to its negative trend over the past week where it has experienced a 2.0% loss, moving from $3.99 to its current price. As it stands right now, the coin's all-time high is $20.44. 
The chart below compares the price movement and volatility for NEAR Protocol over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1725894145_0.png" alt="price_chart" />
The trading volume for the coin has decreased 17.0% over the past week, while the overall circulating supply of the coin has increased 0.76% to over 1.11 billion. The current market cap ranking for NEAR is #25 at $4.26 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1725894145_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$NEAR

Cryptocurrency NEAR Protocol's Price Increased More Than 4% Within 24 hours

Macro Notification

NY Fed 1-Year Consumer Inflation Expectations For August 3.0%	 Vs 3.0% Prior (Unchanged)

UTime Limited ("UTime" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTO#NASDAQ">WTO</a>), a mobile device manufacturing company committed to providing cost effective products and solutions to consumers globally and helping low-income individuals from established and emerging markets today announced that it will effect a reverse share split of its outstanding ordinary shares, par value $0.0001 per share (the "Ordinary Shares"), at a ratio of 1-for-25, to be effective on or around the open of trading on September 11, 2024.
Our Ordinary Shares will begin trading on a reverse share split-adjusted basis at the opening of The Nasdaq Capital Market ("Nasdaq") on or around Wednesday, September 11, 2024. Following the reverse share split, the Ordinary Shares will have a par value of $0.0001 per share and will continue to trade on Nasdaq under the symbol "WTO" with the new CUSIP number, G9411M116. The reverse share split is intended for the Company to regain compliance with the minimum bid price requirement of $1.00 per ordinary share for continued listing on Nasdaq.

Stock Split

UTime Limited Announces 1-For-25 Reverse Share Split, To Be Effective On Or Around The Open Of Trading On September 11, 2024

ADTX

EVFM

Aditxt and Evofem Biosciences shares are trading higher after amending a merger agreement.

Over the past 24 hours, Avalanche's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/avax/usd">AVAX</a>) price has risen 3.73% to $23.46. This continues its positive trend over the past week where it has experienced a 7.0% gain, moving from $22.23 to its current price. As it stands right now, the coin's all-time high is $144.96. 
The chart below compares the price movement and volatility for Avalanche over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1725894075_0.png" alt="price_chart" />
The trading volume for the coin has increased 23.0% over the past week while the overall circulating supply of the coin has increased 0.14% to over 405.26 million which makes up an estimated 56.29% of its max supply, which is 720.00 million. The current market cap ranking for AVAX is #13 at $9.52 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1725894075_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$AVAX

Avalanche Rises More Than 3% In 24 hours

Analysts' ratings for Aramark (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARMK#NYSE">ARMK</a>) over the last quarter vary from bullish to bearish, as provided by 9 analysts.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $38.78, a high estimate of $41.00, and a low estimate of $36.00. Surpassing the previous average price target of $35.78, the current average has increased by 8.38%.
<img src="https://www.benzinga.com/files/images/story/2024/1725894076_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Aramark. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Steinerman</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$41.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Toni Kaplan</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$38.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Gary Bisbee</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$39.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Andrew Steinerman</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$39.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Faiza Alwy</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$39.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Andrew Wittmann</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$38.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Ashish Sabadra</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$36.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Joshua Chan</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$40.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Ian Zaffino</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$39.00</td>
<td>$36.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Aramark. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Aramark compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Aramark's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Aramark's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ARMK/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Aramark analyst ratings.</a>
<h2>About Aramark</h2>
Aramark provides food, facilities, and uniform services to a variety of clients and institutions. The majority of company revenue comes from its North American food and support services segment. Smaller but substantial segments include food and support services international, food and support services united states and uniform and career apparel. The food and support services segments provide food for school districts; colleges; healthcare facilities; correctional institutions; and business, sports, and entertainment venues. The uniform segment rents, delivers, cleans, and maintains work clothes and ancillary items like towels and mats to customers in North America and Japan. The company has hundreds of service locations and distribution centers across the United States and Canada.
<h3>Aramark: Financial Performance Dissected</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Aramark displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 7.97%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Discretionary sector.
Net Margin: Aramark's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 1.33%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Aramark's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 1.99%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Aramark's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.46%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Aramark's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 2.13.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARMK

The Analyst Landscape: 9 Takes On Aramark

During the last three months, 19 analysts shared their evaluations of Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>), revealing diverse outlooks from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">11</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $168.74, with a high estimate of $219.00 and a low estimate of $128.00. Marking an increase of 3.15%, the current average surpasses the previous average price target of $163.58. 
<img src="https://www.benzinga.com/files/images/story/2024/1725894065_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A clear picture of Neurocrine Biosciences's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carter Gould</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$160.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$155.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Evan Seigerman</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$128.00</td>
<td>$142.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$159.00</td>
<td>$131.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$136.00</td>
<td>$143.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$190.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Akash Tewari</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$189.00</td>
<td>$177.00</td>
</tr>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$181.00</td>
<td>$173.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$143.00</td>
<td>$136.00</td>
</tr>
<tr>
<td>Yatin Suneja</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$180.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>David Hoang</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$158.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Jay Olson</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$219.00</td>
<td>$216.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$180.00</td>
<td>$169.00</td>
</tr>
<tr>
<td>Brian Skorney</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$180.00</td>
<td>$157.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$155.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Jeffrey Hung</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$170.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$173.00</td>
<td>$169.00</td>
</tr>
<tr>
<td>Jeffrey Hung</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$160.00</td>
<td>$160.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Neurocrine Biosciences. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Neurocrine Biosciences compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Neurocrine Biosciences's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Neurocrine Biosciences's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/NBIX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Neurocrine Biosciences analyst ratings.</a>
<h2>Delving into Neurocrine Biosciences's Background</h2>
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
<h3>Financial Milestones: Neurocrine Biosciences's Journey</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Neurocrine Biosciences's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 30.37%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Neurocrine Biosciences's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 11.01%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Neurocrine Biosciences's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 2.66%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Neurocrine Biosciences's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.92% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Neurocrine Biosciences's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.1.
<h2>The Basics of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Gain an Edge Using Pro's Market Moving News Breaks — 50% OFF

Gain an Edge Using Pro's Market Moving News Breaks — 50% OFF

Comments

H. Lundbeck

H. Lundbeck (HLBBF) Forecast

H. Lundbeck (OTC:HLBBF) Stock, Quote.Headers.trade-ideas